文献速递神经核医学肿瘤 PET/CT

18F-FDG PET在帕金森综合征中的应用:鉴别诊断与认知障碍评估

18F-FDG PET in Parkinsonism: Differential Diagnosis and Evaluation of Cognitive Impairment.
PubMed 文献 · J Nucl Med · 2017-09-14

该综述指出,18F-FDG PET显像结合基于体素的统计分析可高准确度区分帕金森病与非典型帕金森综合征,初步荟萃分析估计视觉判读诊断非典型帕金森综合征的敏感度和特异度分别为91.4%和90.6%。对多系统萎缩、进行性核上性麻痹和皮质基底节变性,18F-FDG PET诊断特异度持续高(>90%),敏感度更多变(>75%)。近期PET研究还显示,非痴呆帕金森病患者后皮质区功能障碍先于认知下降和帕金森病痴呆发生数年。

要点

  • 18F-FDG PET可高准确度区分帕金森病与非典型帕金森综合征。
  • 视觉判读联合基于体素的统计分析诊断非典型帕金森综合征敏感度91.4%、特异度90.6%。
  • 非痴呆帕金森病患者后皮质区功能障碍可先于认知下降和帕金森病痴呆数年出现。

核心结论

  • 现有文献强调18F-FDG PET对帕金森综合征诊断评估的效用,以及其对帕金森病认知障碍评估和风险分层的应用前景。

研究设计与样本

  • 综述,基于对现有包含多个疾病组研究的初步荟萃分析,评估18F-FDG PET视觉判读联合基于体素的统计分析对非典型帕金森综合征的诊断效能。

主要发现

  • 视觉判读联合基于体素的统计分析诊断非典型帕金森综合征的敏感度为91.4%,特异度为90.6%。
  • 18F-FDG PET诊断多系统萎缩、进行性核上性麻痹和皮质基底节变性的特异度持续高(>90%),敏感度更多变(>75%)。
  • 近期PET研究显示,非痴呆帕金森病患者后皮质区功能障碍先于认知下降和帕金森病痴呆发生数年。

关键数值与推荐

  • 视觉判读联合基于体素的统计分析诊断非典型帕金森综合征:敏感度91.4%,特异度90.6%。
  • 18F-FDG PET诊断多系统萎缩、进行性核上性麻痹和皮质基底节变性:特异度>90%,敏感度>75%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Accurate differential diagnosis of parkinsonism is of paramount therapeutic and prognostic importance. In addition, with the development of invasive therapies and novel disease-specific therapies, strategies for patient enrichment in trial populations are of growing importance. Imaging disease-specific patterns of regional glucose metabolism with PET and 18F-FDG allows for a highly accurate distinction between Parkinson disease (PD) and atypical parkinsonian syndromes, including multiple-system atrophy, progressive supranuclear palsy, and corticobasal degeneration. On the basis of a preliminary metaanalysis of currently available studies with inclusion of multiple disease groups, we estimated that the diagnostic sensitivity and specificity for visual PET readings supported by voxel-based statistical analyses for diagnosis of atypical parkinsonian syndromes are 91.4% and 90.6%, respectively. The diagnostic specificity of 18F-FDG PET for diagnosing multiple-system atrophy, progressive supranuclear palsy, and corticobasal degeneration was consistently shown to be high (>90%), whereas sensitivity was more variable (>75%). It is increasingly acknowledged that cognitive impairment represents a major challenge in PD, with mild cognitive impairment being a prodromal stage of PD with dementia (PDD). In line with clinical and neuropsychologic studies, recent PET studies demonstrated that posterior cortical dysfunction in nondemented PD patients precedes cognitive decline and the development of PDD by several years. Taken together, the current literature underscores the utility of 18F-FDG PET for diagnostic evaluation of parkinsonism and the promising role of 18F-FDG PET for assessment and risk stratification of cognitive impairment in PD.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Meyer PT, Frings L, Rücker G, et al. 18F-FDG PET in Parkinsonism: Differential Diagnosis and Evaluation of Cognitive Impairment. J Nucl Med. 2017. PMID: 28912150. doi:10.2967/jnumed.116.186403

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。